Analysis of cardiac monitoring and safety data in patients initiating fingolimod treatment in the home or in clinic

Analysis of cardiac monitoring and safety data in patients initiating fingolimod treatment in the home or in clinic

Abstract Background Fingolimod (Gilenya®) is approved for relapsing forms of multiple sclerosis in the USA. Owing to transient heart-rate effects when initiating fingolimod, eligible patients undergo precautionary baseline assessment and first-dose observation (FDO) for ≥6 h. Prior to 2014, FDO was...

Full description

Bibliographic Details
Main Authors: Brandon Brown, Jamie L. Weiss, Scott Kolodny, Xiangyi Meng, Ian M. Williams, John A. Osborne
Format: Article
Language:English
Published: BMC 2019-11-01
Series:BMC Neurology
Subjects:
First-dose observation
Gilenya@home
Relapsing–remitting multiple sclerosis
Sphingosine 1-phosphate receptor
Bradycardia
Fingolimod
Online Access:http://link.springer.com/article/10.1186/s12883-019-1506-0

Internet

http://link.springer.com/article/10.1186/s12883-019-1506-0

Similar Items